FrançaisAre analysts right about Amneal Pharmaceuticals (AMRX)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Amneal Pharmaceuticals, we replayed every analyst price target of the past 12 months and measured the real outcome: 60% were profitable, average return +32% (42 calls). At 3 months: +6% average return (40% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Goldman Sachs | 7 | 43% | +32% |
| Truist Securities | 7 | 86% | +98% |
| Piper Sandler | 6 | 83% | +62% |
| Barclays | 5 | 100% | +85% |
Frequently asked questions
Is Amneal Pharmaceuticals a buy right now?
The analyst consensus on Amneal Pharmaceuticals (AMRX) is "Buy" (8 bullish, 0 bearish calls over 12 months). This is not advice: historically, 60% of their targets on this stock turned out profitable over 1 year.
What is Amneal Pharmaceuticals's price target?
The median 12-month price target is $17.00 (-6% vs $18.01), ranging from $16.00 to $25.00 (3 analysts).
Are analysts accurate on Amneal Pharmaceuticals?
Over 1 year, 60% of analyst targets on Amneal Pharmaceuticals were profitable, for an average return of +32% (across 42 timestamped calls). This is JPI Invest's accuracy metric.
What is the Amneal Pharmaceuticals stock forecast?
Analysts target a median of $17.00 within 12 months, i.e. -6% vs the current price. The most bullish targets $25.00, the most cautious $16.00.
What is the Amneal Pharmaceuticals stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $17.00, -6%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (60%), and the stock's past trajectory.
Is Amneal Pharmaceuticals overvalued?
Detailed valuation data for Amneal Pharmaceuticals is available in the interactive analysis.
📊 See the full interactive analysis of Amneal Pharmaceuticals →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.